Safety and tolerability of electronic cigarettes to reduce cigarette smoking: Secondary analysis from a randomized placebo-controlled trial

This secondary analysis of a randomized placebo-controlled trial involving 520 adults found that while electronic cigarettes were generally well-tolerated with no serious adverse events, they caused significantly higher rates of mild symptoms like cough, headache, and sore throat compared to non-aerosol substitutes, particularly when containing nicotine.

The Gist

Imagine your body is a busy city, and smoking cigarettes is like dumping toxic trash into the streets every day. For years, we've known this trash causes massive problems (heart disease, cancer, etc.). Now, people are trying to switch to "electric delivery trucks" (e-cigarettes) to stop dumping the toxic trash, hoping these trucks are cleaner.

But here's the big question: Are these electric trucks actually safe to drive, or do they just dump a different kind of mess?

This study is like a 6-month traffic safety report for those electric trucks. Researchers took 520 people who were trying to drive fewer "toxic trash trucks" (cigarettes) and gave them different vehicles to test:

1. The "Empty" Truck: An e-cigarette with no nicotine (just the flavor and vapor).
2. The "Low-Power" Truck: An e-cigarette with a little nicotine (8 mg).
3. The "High-Power" Truck: An e-cigarette with a lot of nicotine (36 mg).
4. The "Dummy" Truck: A plastic tube that looks like a cigarette but has no electronics, no vapor, and no nicotine. This is the control group—the "placebo."

The Main Findings: What Happened on the Road?

1. The "Dummy" Truck was the Smoothest Ride
People using the plastic tube (the control group) barely had any complaints. It was like driving a car with the engine off; nothing happened, so nothing went wrong. Only about 2.5% of them reported any issues related to the study.

2. The E-Cigarettes Had Some "Bumps in the Road"
When people started using the real e-cigarettes (the ones with vapor), they reported more minor annoyances.

• The "Cough" Bump: This was the most common complaint. About 8.5% more people in the e-cigarette groups coughed compared to the plastic tube group.
• The "Headache" and "Sore Throat" Bumps: These were also more common in the e-cigarette groups.

Think of it like this: If you switch from driving a loud, smoky old truck to a quiet electric car, you might still get a little vibration or a weird noise from the new engine. It's not a crash (no one died or was seriously hurt), but it's definitely noticeable.

3. The "Nicotine Fuel" Made the Bumps Worse
The study found that the High-Power Trucks (36 mg nicotine) and Low-Power Trucks (8 mg) had more complaints than the Empty Truck (0 mg).

• Specifically, coughing was much more common in the groups using nicotine.
• It's as if the "fuel" (nicotine) made the engine run a bit hotter, irritating the throat and lungs more than just the vapor alone.

4. No Major Crashes
Here is the most important part: No one had a serious accident.

• There were no "fatalities" or "hospitalizations" caused by the e-cigarettes.
• Almost all the complaints (coughs, headaches, sore throats) were mild. They were annoying, like a scratch on your car, but they didn't break the engine.
• Very few people (only 4 out of 520) had to quit the study because of these minor issues.

The Big Picture: What Does This Mean?

The Good News:
If you are trying to quit smoking cigarettes, switching to these e-cigarettes seems safe for the short term (at least for 6 months). The "trash" you are breathing in is likely much less dangerous than the toxic smoke from a real cigarette. The side effects are mostly just annoying throat tickles and headaches, not life-threatening diseases.

The "But..." (The Caveats):

• It's not perfect: E-cigarettes aren't "harmless." They do irritate your body more than doing nothing (or using a plastic tube).
• The Nicotine Factor: If you use a lot of nicotine, you are more likely to get those annoying side effects like coughing.
• The "Dual-Use" Problem: Most people in this study were still smoking real cigarettes while using the e-cigarettes. It's like driving two cars at once. The study suggests that even with this messy situation, the e-cigarettes didn't cause major new disasters.

The Takeaway Analogy

Imagine you are trying to stop eating deep-fried, greasy burgers (cigarettes) because they are terrible for your health.

• The plastic tube is like eating a plain, tasteless cracker. It's safe, but it doesn't satisfy your craving.
• The e-cigarettes are like grilled burgers. They aren't as bad as the deep-fried ones, but they still have some grease and seasoning that might give you a little heartburn or a sore throat (the cough/headache).
• The nicotine is like adding extra spicy sauce. It makes the burger taste more like the real thing, but it also makes the heartburn slightly worse.

Conclusion:
The study tells us that switching to e-cigarettes is like switching from deep-fried burgers to grilled ones. You might get a little heartburn (coughing, sore throat), especially if you add extra spice (nicotine), but you aren't going to have a heart attack from it. It's a safer option for your city, but you still need to watch out for those minor bumps in the road.

Technical Summary

1. Problem Statement

While electronic cigarettes (e-cigarettes) are increasingly used as harm-reduction tools to help smokers reduce combustible cigarette consumption, the clinical safety profile of their use—specifically regarding adverse events (AEs)—remains poorly characterized. Existing literature often lacks robust, long-term data from controlled trials, particularly concerning:

• The comparative safety of e-cigarettes with varying nicotine concentrations (0, 8, and 36 mg/mL).
• The distinction between AEs caused by the device/aerosol (e.g., propylene glycol, vegetable glycerin) versus those caused by nicotine.
• The frequency and severity of non-serious but common symptoms (e.g., cough, headache) that may affect adherence and user experience.
• The need for standardized safety monitoring to inform regulatory decisions and clinical guidance.

2. Methodology

Study Design:
This study is a secondary analysis of a 6-month, double-blind, four-arm, parallel-group, randomized controlled trial (RCT) involving 520 adult smokers (aged 21–65) who smoked $\ge$10 cigarettes/day and were interested in reducing consumption.

Intervention Groups:
Participants were randomized to one of four conditions:

1. E-cigarette with 0 mg/mL nicotine (placebo e-liquid).
2. E-cigarette with 8 mg/mL nicotine.
3. E-cigarette with 36 mg/mL nicotine.
4. Cigarette Substitute (CS): A non-aerosol, non-nicotine plastic tube (control).

Procedure:

• Duration: 6-month intervention period followed by 3 months of follow-up.
• Goal: Participants were encouraged to reduce combustible cigarette use by 50% for 2 weeks, then 75% for 2 weeks, maintaining that reduction for the remainder of the trial.
• Device: eGo-style devices with tobacco or menthol flavors (chosen by participant). The 36 mg/mL liquid delivered a blood nicotine boost (13 ng/mL) comparable to smoking a cigarette (15 ng/mL).

Data Collection & Analysis:

• Adverse Events (AEs): Collected via standardized trigger questions at weeks 1, 2, 4, 8, 12, 16, 20, and 24.
• Coding: AEs were coded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v4.0 and MedDRA preferred terms.
• Classification: AEs were assessed for frequency, severity (mild to fatal), seriousness (hospitalization, death, etc.), and relatedness (unrelated, unlikely, possible, probable, definite).
• Primary Focus: "Study-related AEs" (rated as possibly, probably, or definitely related to the product or study procedures).
• Statistical Approach:
  • Risk Differences (RD) with 95% Confidence Intervals (CIs) calculated using nonparametric bootstrapping (g-computation).
  • Fisher's exact test with False Discovery Rate (FDR) adjustment for multiple comparisons.
  • Cumulative incidence of the first study-related AE estimated via Kaplan-Meier methods.

3. Key Contributions

• Comparative Safety Profile: Provides one of the first direct comparisons of AE profiles across three distinct nicotine concentrations and a non-aerosol control in a double-blind setting.
• Differentiation of Nicotine vs. Aerosol Effects: Isolates the impact of nicotine by comparing nicotine-containing groups against the 0 mg/mL group, and the impact of aerosol by comparing all e-cigarette groups against the cigarette substitute.
• Methodological Rigor: Utilizes a placebo-controlled design with a non-aerosol control, addressing a common limitation in previous e-cigarette safety studies where "no treatment" or "behavioral support" groups were used instead of a physical placebo.
• Focus on Tolerability: Shifts focus from solely Serious Adverse Events (SAEs) to the frequency of mild-to-moderate symptoms that impact user adherence and tolerability.

4. Key Results

Overall Safety:

• Seriousness: No study-related Serious Adverse Events (SAEs) were reported. One fatal event (suicide) occurred in the 0 mg/mL group but was deemed unrelated to the study.
• Severity: The vast majority of study-related AEs were mild. Only 4 participants experienced severe study-related AEs (hypertension, dyspnea, cough, syncope).
• Withdrawals: Only 4 participants (0.8%) withdrew due to study-related AEs (3 in the 36 mg/mL group, 1 in the 0 mg/mL group).

Incidence of Study-Related AEs:

• Cumulative Incidence (24 weeks):
  • 36 mg/mL group: 37.0%
  • 8 mg/mL group: 35.2%
  • 0 mg/mL group: 23.4%
  • Cigarette Substitute (CS) group: 2.5%
• Comparison (E-cigarette vs. CS): E-cigarette users had significantly higher risks of:
  • Cough: RD 8.5% (95% CI: 5.6 – 11.3)
  • Headache: RD 5.4% (95% CI: 3.3 – 7.6)
  • Sore Throat: RD 5.4% (95% CI: 3.2 – 7.6)
• Comparison (Nicotine vs. Non-Nicotine):
  • Cough: Significantly higher in nicotine groups (8 mg/mL and 36 mg/mL combined) vs. 0 mg/mL (RD 8.1%, 95% CI: 3.4 – 12.8).
  • Other Respiratory Symptoms: Significantly higher in the 36 mg/mL group vs. 0 mg/mL (4.6% vs. 0%).
  • No significant differences were found for headache or sore throat between nicotine and non-nicotine groups.

Most Common AEs:
The most frequently reported study-related AEs were cough (6.3%), headache (4.0%), sore throat (4.0%), mouth ulcers (2.3%), and nausea (2.1%). Most were mild in severity.

5. Significance and Implications

• Clinical Practice: The findings suggest that e-cigarettes are generally well-tolerated in the short term for smokers attempting to reduce consumption. However, clinicians should counsel patients that mild respiratory and systemic symptoms (cough, headache, sore throat) are common, particularly with nicotine-containing products, and may affect adherence.
• Regulatory Policy: The data supports the safety of short-term e-cigarette use for harm reduction but highlights the need for regulators to monitor specific symptom profiles (cough, throat irritation) when evaluating new products, especially those with high nicotine concentrations.
• Public Health: While e-cigarettes carry a higher risk of mild AEs compared to a non-aerosol substitute, the absence of serious study-related events and the manageable nature of the symptoms support their role as a less harmful alternative to combustible cigarettes for dual users.
• Future Research: The study underscores the need for long-term safety monitoring and standardized AE reporting across evolving product types (e.g., nicotine salts) and diverse populations, as this trial utilized second-generation free-base nicotine devices.

Limitations Noted:

• The cigarette substitute arm could not be blinded, potentially inflating the perceived risk difference.
• The study utilized second-generation free-base nicotine, which differs from newer nicotine salt formulations.
• Participants were screened for health stability, meaning the safety profile may not fully reflect real-world use among those with unstable chronic conditions.